Below are the most recent publications written about "Piperidines" by people in Profiles.
-
Verheij VA, Diecidue RJ, Botman E, Harrington JD, Haga N, Hidalgo-Bravo A, Delai PLR, Madhuri V, Al Mukaddam M, Zhang K, Cho TJ, Morhart R, Keen R, De Cunto CL, Friedman CS, Grunwald Z, Zasloff M, Netelenbos JC, Hsiao E, Kaplan FS, Pignolo RJ, Scott C, Eekhoff EMW. Palovarotene in fibrodysplasia ossificans progressiva: review and perspective. Expert Opin Pharmacother. 2025 Feb; 26(3):291-299.
-
Hao H, Yin T, Li T, Zhou X, Ren H, Liu M, Huang H, Qi C, Xiu Y, Qiu W, Wang D, Shi M, Wang X, Dumont AS, Liu Q. Inhibition of Bruton's tyrosine kinase restricts neuroinflammation following intracerebral hemorrhage. Theranostics. 2025; 15(2):494-508.
-
Regnault A, Bunod L, Loubert A, Brose MS, Hess LM, Maeda P, Lin Y, Speck RM, Gilligan AM, Payakachat N. Assessing tolerability with the Functional Assessment of Cancer Therapy item GP5: psychometric evidence from LIBRETTO-531, a phase 3 trial of selpercatinib in medullary thyroid cancer. J Patient Rep Outcomes. 2024 Dec 19; 8(1):149.
-
Castro E, Wang D, Walsh S, Craigie S, Haltner A, Nazari J, Niyazov A, Samjoo IA. Talazoparib plus enzalutamide versus olaparib plus abiraterone acetate and niraparib plus abiraterone acetate for metastatic castration-resistant prostate cancer: a matching-adjusted indirect comparison. Prostate Cancer Prostatic Dis. 2025 Sep; 28(3):817-827.
-
Arciniegas DB, Almeida EJ, Sander AM, Bogaards JA, Giacino JT, Hammond FM, Harrison-Felix CL, Hart T, Ketchum JM, Mellick DC, Sherer M, Whyte J, Zafonte RD. Multicenter Evaluation of Memory Remediation in Traumatic Brain Injury With Donepezil: A Randomized Controlled Trial. J Neuropsychiatry Clin Neurosci. 2025; 37(2):102-114.
-
Cosentino G, Dichiara M, Ambrosio FA, Leotta CG, Costa G, Procopio F, Costanzo G, Raffa A, Artacho-Cord?n A, Ruiz-Cantero MC, Pasquinucci L, Marrazzo A, Pitari GM, Cobos EJ, Alcaro S, Amata E. Development of selective sigma-1 receptor ligands with antiallodynic activity: A focus on piperidine and piperazine scaffolds. Eur J Med Chem. 2025 Jan 05; 281:117037.
-
Lopez CD, Kardosh A, Chen EY, Pegna G, Guimaraes A, Foster B, Brinkerhoff B, Goodyear SM, Lim JY, Taber E, Rajagopalan B, Edmerson E, Vo J, Nelson K, Jackson A, Gingerich T, Fahlman A, Lessenich C, Fennell F, Ventura D, Roy P, Keith D, Sheppard B, Brody JR, Mills GB, Ronai ZA, Sears RC. CASPER: A Phase I trial combining calaspargase pegol-mnkl and cobimetinib in pancreatic cancer. Future Oncol. 2024; 20(37):2915-2925.
-
Monk BJ, Barretina-Ginesta MP, Pothuri B, Vergote I, Graybill W, Mirza MR, McCormick CC, Lorusso D, Moore RG, Freyer G, O'Cearbhaill RE, Heitz F, O'Malley DM, Redondo A, Shahin MS, Vulsteke C, Bradley WH, Haslund CA, Chase DM, Pisano C, Holman LL, P?rez MJR, DiSilvestro P, Gaba L, Herzog TJ, Bruchim I, Compton N, Shtessel L, Malinowska IA, Gonz?lez-Mart?n A. Niraparib first-line maintenance therapy in patients with newly diagnosed advanced ovarian cancer: final overall survival results from the PRIMA/ENGOT-OV26/GOG-3012 trial. Ann Oncol. 2024 Nov; 35(11):981-992.
-
Ailani J, Gandhi P, Lalla A, Halker Singh R, McAllister P, Smith JH, Dabruzzo B, Chalermpalanupap N, Kelton K, Nahas SJ. Cost per treatment responder analysis of atogepant compared to rimegepant for the preventive treatment of episodic migraine. Headache. 2024 Nov-Dec; 64(10):1253-1263.
-
Talasila S, Lee E, Teichner EM, Siegfried EC, Jackson Cullison SR. Analysis of publicly available adverse events reported for pediatric patients treated with Janus kinase inhibitors. Pediatr Dermatol. 2024 Nov-Dec; 41(6):1040-1046.